Credit Suisse’s Pfizer PFE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q1 | $239M | Sell |
8,614,681
-363,142
| -4% | -$10.1M | 0.23% | 80 |
|
|
2023
Q4 | $258M | Sell |
8,977,823
-945,852
| -10% | -$28.6M | 0.25% | 70 |
|
|
2023
Q3 | $329M | Buy |
9,923,675
+346,059
| +4% | +$12.2M | 0.33% | 51 |
|
|
2023
Q2 | $351M | Buy |
9,577,616
+228,250
| +2% | +$8.88M | 0.35% | 46 |
|
|
2023
Q1 | $381M | Sell |
9,349,366
-40,831
| -0.4% | -$1.76M | 0.38% | 42 |
|
|
2022
Q4 | $481M | Buy |
9,390,197
+292,873
| +3% | +$14M | 0.51% | 30 |
|
|
2022
Q3 | $398M | Buy |
9,097,324
+332,560
| +4% | +$16.2M | 0.44% | 35 |
|
|
2022
Q2 | $460M | Buy |
8,764,764
+183,604
| +2% | +$9.36M | 0.48% | 32 |
|
|
2022
Q1 | $444M | Buy |
8,581,160
+14,649
| +0.2% | +$760K | 0.38% | 42 |
|
|
2021
Q4 | $506M | Buy |
8,566,511
+513,574
| +6% | +$25.4M | 0.27% | 55 |
|
|
2021
Q3 | $346M | Sell |
8,052,937
-788,563
| -9% | -$34.9M | 0.19% | 86 |
|
|
2021
Q2 | $346M | Sell |
8,841,500
-4,655,373
| -34% | -$181M | 0.18% | 85 |
|
|
2021
Q1 | $489M | Sell |
13,496,873
-4,663,475
| -26% | -$166M | 0.25% | 65 |
|
|
2020
Q4 | $668M | Buy |
18,160,348
+4,038,311
| +29% | +$148M | 0.33% | 50 |
|
|
2020
Q3 | $492M | Buy |
14,122,037
+541,625
| +4% | +$19M | 0.3% | 57 |
|
|
2020
Q2 | $421M | Sell |
13,580,412
-2,415,095
| -15% | -$82M | 0.3% | 59 |
|
|
2020
Q1 | $495M | Buy |
15,995,507
+898,503
| +6% | +$30.6M | 0.43% | 36 |
|
|
2019
Q4 | $561M | Buy |
15,097,004
+888,861
| +6% | +$31.7M | 0.41% | 35 |
|
|
2019
Q3 | $484M | Buy |
14,208,143
+1,217,853
| +9% | +$44.3M | 0.41% | 35 |
|
|
2019
Q2 | $534M | Buy |
12,990,290
+1,335,944
| +11% | +$53M | 0.47% | 26 |
|
|
2019
Q1 | $470M | Sell |
11,654,346
-2,664,438
| -19% | -$107M | 0.43% | 29 |
|
|
2018
Q4 | $593M | Sell |
14,318,784
-739,677
| -5% | -$30.7M | 0.62% | 21 |
|
|
2018
Q3 | $630M | Buy |
15,058,461
+344,875
| +2% | +$13.3M | 0.56% | 22 |
|
|
2018
Q2 | $506M | Sell |
14,713,586
-426,155
| -3% | -$14.6M | 0.5% | 23 |
|
|
2018
Q1 | $510M | Sell |
15,139,741
-1,360,863
| -8% | -$46.8M | 0.48% | 32 |
|
|
2017
Q4 | $567M | Buy |
16,500,604
+1,293,466
| +9% | +$44.1M | 0.51% | 28 |
|
|
2017
Q3 | $515M | Sell |
15,207,138
-119,854
| -0.8% | -$3.85M | 0.5% | 22 |
|
|
2017
Q2 | $488M | Sell |
15,326,992
-3,678,861
| -19% | -$116M | 0.48% | 30 |
|
|
2017
Q1 | $617M | Buy |
19,005,853
+1,665,779
| +10% | +$52.5M | 0.56% | 25 |
|
|
2016
Q4 | $534M | Buy |
17,340,074
+621,905
| +4% | +$19M | 0.53% | 26 |
|
|
2016
Q3 | $537M | Buy |
16,718,169
+715,644
| +4% | +$23.9M | 0.51% | 27 |
|
|
2016
Q2 | $535M | Sell |
16,002,525
-9,556,317
| -37% | -$305M | 0.59% | 24 |
|
|
2016
Q1 | $719M | Buy |
25,558,842
+3,621,894
| +17% | +$103M | 0.87% | 8 |
|
|
2015
Q4 | $672M | Buy |
21,936,948
+4,923,802
| +29% | +$155M | 0.77% | 10 |
|
|
2015
Q3 | $507M | Sell |
17,013,146
-4,196,979
| -20% | -$135M | 0.61% | 15 |
|
|
2015
Q2 | $675M | Sell |
21,210,125
-261,428
| -1% | -$8.52M | 0.66% | 17 |
|
|
2015
Q1 | $709M | Buy |
21,471,553
+472,143
| +2% | +$15M | 0.72% | 13 |
|
|
2014
Q4 | $1.39B | Sell |
20,999,410
-1,689,365
| -7% | -$48.4M | 1.23% | 4 |
|
|
2014
Q3 | $637M | Buy |
22,688,775
+2,226,353
| +11% | +$62.5M | 0.52% | 24 |
|
|
2014
Q2 | $576M | Buy |
20,462,422
+1,423,324
| +7% | +$40.6M | 0.47% | 23 |
|
|
2014
Q1 | $580M | Buy |
19,039,098
+722,334
| +4% | +$21.5M | 0.57% | 20 |
|
|
2013
Q4 | $532M | Sell |
18,316,764
-437,319
| -2% | -$12.7M | 0.48% | 24 |
|
|
2013
Q3 | $511M | Sell |
18,754,083
-29,417,647
| -61% | -$800M | 0.51% | 24 |
|
|
2013
Q2 | $1.28B | Buy |
+48,171,730
| New | +$1.33B | 1.29% | 5 |
|
Other funds holding PFE
Credit Suisse's PFE Position: Q1 2024 in Review
Credit Suisse reduced its Pfizer (PFE) stake by 4% in Q1 2024, selling an estimated $10.1M and leaving 8,614,681 shares worth $239M. The position accounts for 0.23% of the portfolio, ranked #80.
Credit Suisse first reported a position in PFE in Q2 2013 and has held it in 44 quarters since. The position peaked at $1.39B in Q4 2014. 2,874 funds tracked by Wall St. Rank hold PFE as of Q1 2024.
- Credit Suisse held 8,614,681 shares of Pfizer worth $239M as of Q1 2024.
- Credit Suisse sold 363,142 Pfizer shares in Q1 2024, an estimated $10.1M.
- Pfizer made up 0.23% of Credit Suisse's portfolio in Q1 2024, its #80 holding.
- Credit Suisse first reported a position in Pfizer in Q2 2013 and has held it in 44 quarters since.
- Credit Suisse's Pfizer position peaked at $1.39B in Q4 2014.
- 2,874 funds tracked by Wall St. Rank held Pfizer as of Q1 2024.
Based on Credit Suisse's 13F filing for Q1 2024, filed 10 May 2024.